Integrin-linked kinase (ILK) and p38
INTRODUCTION

The p38
MAPK protein kinases comprise a family of four related isoforms, a, b, d and g that have key roles in regulating inflammation, proliferation, differentiation, cell cycle, apoptosis and tumorigenesis. 1 Various extracellular stimuli induce phosphorylation and activation of p38 mitogen-activated protein kinase (MAPK) by MAPK kinases (MKKs), including ultraviolet light, osmotic shock, inflammatory cytokines and growth factors. Responses to p38 activation are also dependent on cell type, contributing further to the complexity of signaling by this family of MAPKs. The defining family member, p38a, was discovered as a target of lipopolysaccharide-induced tyrosine phosphorylation and an effector of pro-inflammatory cytokine production. Among the four p38 MAPK family members, p38d and p38g exhibit more restricted tissue distribution than p38a and p38b isoforms, and are insensitive to pyridinyl imidazole inhibitors (for example, SB203580), which inhibit p38a and p38b. 2 Although p38a and p38b share 70% amino acid identity and overlapping substrate selectivity, genetic analysis in mice indicates that p38b cannot substitute for essential embryonic functions of p38a. 3 The four isoforms are activated through dual phosphorylation by the upstream MKKs, which are themselves differentially activated by distinct extracellular signals to regulate cell-and stimulus-specific p38 MAPK signaling. For example, although both MKK3 and MKK6 are required for activation of p38b and p38g by environmental stress, activation of p38g by tumor necrosis factor-a requires MKK3 only. 4 Further, isoform-specific structural determinants regulate distinct subcellular localizations and activities of complexes between p38a or p38b, and the p38-regulated/activated kinase (PRAK). 5 
Although p38
MAPK signaling has been intensely studied in inflammatory cells, 2 p38 also inhibits tumor growth and/or promotes apoptosis, thus p38 MAPKs can act to suppress tumorigenesis. 6 Interestingly, MKK expression is frequently absent or downregulated in bladder carcinoma, although these cells exhibit normal levels of p38 MAPKs, suggesting alternative regulation of p38 signaling in bladder cancer cells. 7 Moreover, bioinformatic analyses of clinical samples 8 and cell biological 9 data, implicate dysregulated p38 MAPK signaling in early and late stages of bladder cancer progression. Pathway analysis of 56 bladder cancer cases identified upregulated transcription factors in the p38 MAPK signaling pathway associated with carcinoma in situ, a lesion considered to be a precursor to invasive bladder cancer. Activation of p38 MAPK in some tumors such as melanoma 10 suggests an attractive target for cancer-specific therapeutics aimed at suppressing aberrantly activated p38 signaling. Most p38 MAPK studies have focused on the ubiquitously expressed a and b isoforms, which are sensitive to pyridinyl imidazole inhibitors, 2 and these small molecules are currently being trialed as anti-cancer and anti-inflammatory drugs.
Like p38, integrin-linked kinase (ILK) is a ubiquitously expressed protein kinase that is implicated in cellular responses to lipopolysaccharide. 12 ILK was discovered in a yeast two-hybrid screen for b1 integrin-binding partners, 13 and genetic experiments in flies, 14 worms 15 and mice 16 subsequently confirmed that ILKnull embryos die due to early integrin-associated cytoskeletal and cell attachment defects. Thus, ILK deletion in mice causes periimplantation death due to profound disorganization of the epiblast actin cytoskeleton. 16 Importantly, in a broad range of normal and cancer cells, ILK signaling has been shown to mediate motility and migration, cellular processes underpinned by integrin-induced remodeling of the actin cytoskeleton. 17, 18 ILK is highly expressed in invasive bladder cancer cells and promotes growth of bladder cancer xenografts in nude mice. 19, 20 At focal adhesions, ILK binds to the adapter protein b-parvin, which directly associates with the Rac1/Cdc42-specific guanine exchange factor, a-PIX, linking ILK to Rac1-mediated actin cytoskeleton remodeling in cell culture 21 and in vivo. 22 Small interfering RNA (siRNA)-mediated depletion of cellular ILK has been shown to destabilize its focal adhesion binding partner a-parvin, suggesting that ILK scaffolding protects a core, integrin-dependent focal complex from proteasomal degradation.
A few studies have linked ILK and p38 signaling during mammalian development and in cells treated with growth or morphogenetic factors. We observed ILK-dependent activation of p38 MAPK and its downstream effector the ATF-2 transcription factor, during BMP7-induced morphogenesis in renal collecting duct cells in vitro. 23 Moreover, ILK mediates p38 MAPK -dependent cell cycle arrest during ureteric bud development in vivo. 24 Recent work has also suggested that an ILK-p38 signaling axis regulates platelet-derived growth factor-induced migration of vascular smooth muscle cells, 25 thus p38 is established as an important target of ILK-regulated developmental processes in different cell types. However, although these studies have highlighted key regulatory interactions of ILK with p38 MAPK in development and tissue homeostasis, none have implicated specific p38 MAPK isoforms in ILK signaling.
In studying ILK-related signaling pathways in paired normal and cancerous bladder tissues, we observed a striking positive correlation between levels of ILK and the p38b isoform. We show that ILK and p38b promote migration of bladder cancer cells, and demonstrate selective formation of a cytoplasmic complex with ILK in these cells, which acts to stabilize p38b protein levels. Interestingly, the ILK/p38b complex does not affect Rac1 activity, but does modulate phosphorylation of the repeated heat shock protein 27 (Hsp27), which has been associated with actin remodeling, cell migration and metastasis. Our data identify a novel ILK-p38b signaling axis that regulates motility in bladder cancer cells, with potential for therapeutic targeting.
RESULTS
Strong positive correlation between ILK and p38b protein levels in bladder tissue
We surveyed mRNA and protein levels of all four p38 isoforms and ILK protein expression in a series of cell lines derived from normal bladder urothelium and bladder cancers. Real-time quantitative PCR indicated that p38a, b and g are expressed in TSU-Pr1 cells (Supplementary Figure S1a) . However, western blot analyses using isoform-specific p38 antibodies, indicated that p38b is the predominant isoform present in the urothelial and bladder cancer lines, including normal urothelial cells, SV-HUC1 (Figure 1a , Supplementary Figure S1d ). This discordance between isoform expression and protein levels indicates significant post-transcriptional regulation of p38 isoforms in bladder cancer cells. Interestingly, we also observed a trend toward increased p38b levels that paralleled the increase in migratory behavior reported for these cells. 20 In order to further investigate a functional relationship between ILK and p38b, we examined the TSU-Pr1 cells in greater detail for molecular interactions between these two proteins.
We have previously selected and derived two variants of TSU-Pr1 and showed that they form a graded migration series: TSU-Pr14TSU-Pr1-B14TSU-Pr1-B2 26 (Supplementary Figure S2a) . ILK protein was readily detectable in all cell lines and interestingly, we observed that both ILK and p38b protein levels increased in parallel with the migratory capacity in the TSU-Pr1 series (Figure 1a) . Moreover, as indicated by western blotting using phospho p38 (Thr180/Tyr182) antibody, p38b is activated in all three TSU-Pr1 variants (Figures 1b and c) . In order to ascertain whether the association of ILK and p38b is evident in human bladder carcinoma, we analyzed protein levels of ILK and p38b in paired samples of normal and invasive bladder cancer tissues. In this series, four of five samples (paired samples 06, 39, 62, 71, 90) showed higher levels of both ILK and p38b compared with normal tissue and a strong (P ¼ 0.007) positive correlation between levels of these proteins was observed for the samples (Figures 1d-g ). Two samples in our cohort did not have detectable GAPDH protein by western blotting (Figure 1d ) and were omitted from further analysis. We next analyzed expression of the p38 regulators MKK3 and MKK6 in these cell lines, by quantitative PCR and western blotting. Expression of MKK6 was significantly lower in the TSU-Pr1 series than in the 5637 or SV-HUC1 normal urothelial cells, and overall much lower than MKK3 message levels. MKK3 protein was readily detected in normal urothelial cells and in the TSU-Pr1 series, whereas MKK6 protein was almost undetectable in these cells, as assessed by western blotting (Supplementary Figure S1b,e) .
Inhibiting ILK or p38b inhibits cell migration and disrupts actin organization Given the direct correlation of activated p38b with migratory strength in TSU-Pr1 variants, we investigated ILK as a potential regulator of p38b signaling in the TSU-Pr1 parent cells. We chose to analyze migration using two independent assays, monolayer wound healing and chemotaxis. We first confirmed that siRNAmediated knockdown of p38b or ILK did not affect TSU-Pr1 cell viability (Supplementary Figure S2b) . In monolayer migration assays, wound closure of cells with 90% p38b knockdown was modestly inhibited relative to p38g and non-target control (NTC) siRNA-transfected cells (Figures 2a-c) . Next, we analyzed directional migration toward fetal bovine serum (FBS) in chemotaxis assays, which is a more relevant assay than wound healing for assessing metastatic potential. 27 In these assays, siRNA-mediated depletion of p38b protein inhibited FBS-induced chemotactic migration by about 75%, whereas p38g control siRNA had no effect on p38b protein level or cell migration, relative to NTC siRNA controls (Figures 2c-e) . We next investigated the role of ILK in wound healing and chemotaxis assay (Figures 2f-j) . ILK siRNA depleted protein levels by 480% in the TSU-Pr1 cells (Figure 2i ) and, like p38b knockdown, had only a modest inhibitory effect on wound closure (Figures 2f and g ). However, in the chemotaxis assay this level of ILK depletion inhibited FBS-induced cell migration by about 60% (Figures 2h and j) , similar to p38b knockdown. Transfection of p38b did not significantly reverse the chemotactic defect in the ILK-depleted cells (Supplementary Figure S3) , supporting functional interaction of these two proteins to regulate this migration. Taken together, these results suggest that ILK and p38b regulate serum-induced directional migration of TSU-Pr1 cells.
We next examined the effects of ILK and p38b knockdown on actin cytoskeletal organization. ILK and p38b siRNAs caused marked changes in cell shape during chemotactic migration (Figure 3a) , and affected actin dynamics, as the ratio of filamentous (F) to monomeric (G) actin was significantly reduced in ILK-or p38b deficient cells (Figures 3b-d) . These results suggested that ILK and p38b regulate Rho family GTPases in these cells. In particular, ILK has been implicated in regulating Rac1-dependent cell migration in other cell types, through bparvin-mediated interaction with Rac1 guanine exchange factor, a-PIX. 28 We observed that FBS-induced migration of TSU-Pr1 cells was dependent on Rac1, using the selective small molecule Rac1 inhibitor NSC23766 (Gao et al. 29 ; Supplementary Figure S4a) . We therefore examined FBS-induced activation of Rac1 in cells depleted of ILK or p38b by siRNA. Surprisingly, although Rac1 activation was readily apparent in control experiments, we observed no difference in FBS-induced Rac1:GTP activation levels between cells transfected with NTC, ILK, p38b or p38g siRNAs (Supplementary Figure S4b-d) . As we had observed low to undetectable b-parvin or a-PIX mRNA levels in TSU-Pr1 cells (Supplementary Figure S1c) , this suggested a novel mechanism underlying ILK regulation of Rac1-dependent cell migration in these cells. Thus, in order to identify a potential target of p38b/ILK regulation that is relevant to cell migration, we searched p38 signaling pathways in the ONCOMINE database and identified Hsp27 mRNA as significantly upregulated in bladder cancer cells. Hsp27 is an indirect p38a/b target that regulates actin remodeling and cell migration. 30, 31 Therefore, we analyzed activating phosphorylation of Hsp27 in ILK-depleted TSU-Pr1 cells. ILK siRNA-mediated knockdown in the TSU-Pr1 cells both delayed the onset and suppressed the magnitude of serum-induced Hsp27 induction of p38 phosphorylation using the phospho-p38 (Thr180/ Tyr182) antibody. Indeed, ILK knockdown markedly reduced this activating p38b phosphorylation (Figure 5a ), consistent with our earlier findings in kidney epithelial cells 23 and suggesting that ILK mediates activation of p38b in a TSU-Pr1 promigratory pathway. Surprisingly, however, we observed that the reduced p38b Tyr180/ Tyr182 phosphorylation in ILK knockdown cells resulted from a significantly reduced level of total p38b protein in these cells (Figure 5a ), indicating that ILK either stabilizes p38b protein or regulates its expression. Again, this effect of ILK is selective for p38b, as cellular levels of Akt and GSK3b are not affected by ILK knockdown (Figure 5a ). We then analyzed expression levels of all four p38 mRNA isoforms in ILK-depleted TSU-Pr1 cells, in order to determine whether ILK regulates p38 MAPK transcription. quantitative PCR analysis of ILK-depleted TSU-Pr1 cells indicated no reduction in the levels of any p38 isoform message, and in fact p38b expression was increased in ILK-depleted cells (Figure 5b) . Thus, ILK regulates p38b at the post-transcriptional level, and we therefore tested the possibility that p38b protein is specifically destabilized in ILK-depleted cells. FLAG-tagged p38b and p38g isoforms were transfected into TSU-Pr1 cells, which had been previously transfected with ILK siRNA to knockdown ILK, or with NTC control siRNA. In the ILK-depleted cells, FLAG-p38b, but not FLAG-p38g, levels were reduced by about 63% (Figure 5c ), providing evidence that ILK selectively stabilizes p38b. As with endogenous p38b, we found that residual FLAG-tagged p38b was phosphorylated in ILK-depleted and control cells (Figure 5c ). Treatment of ILK-depleted cells with the 26S proteasome inhibitor, MG132, resulted in a concentration-dependent increase in p38b protein levels relative to vehicle-treated control cells (Figure 5d ). Thus, partial rescue of p38b levels by MG132 in the ILK-depleted cells suggests ILK-dependent protection of the p38b isoform from proteasomal degradation.
ILK and p38b form serum-modulated cytoplasmic complexes ILK is known to bind to and stabilize focal adhesion proteins such as a-parvin, thus, we next tested whether ILK and p38b form complexes, which could function to stabilize p38b. FLAG-tagged p38-b or -g complementary DNAs were transfected into TSU-Pr1 cells, followed by immunoprecipitation with FLAG antibody. We tested appropriate expression of FLAG-tagged constructs using immunofluorescence and by subcellular fractionation, which confirmed that both exogenous and endogenous p38b were expressed cytoplasmically, whereas FLAG-p38g localized in the nucleus of cells (Supplementary Figure S5) . Immunoblotting indicated significant levels of ILK protein in nuclear and cytoplasmic fractions (Supplementary Figure S5b) . We then examined formation of ILK-p38b complexes by performing western blotting on ILK immunoprecipitates using a FLAG antibody. FLAG-p38b, but not FLAG-p38g was detected in ILK immune complexes, indicating specific association of ILK and p38b (Figure 6a ). In order to confirm this interaction, we analyzed ILK-p38b association in living cells using bimolecular fluorescent complementation (BiFC), which detects a reconstituted fluorescent signal due to direct interaction between two proteins that have been respectively tagged with non-fluorescent, N-and C-terminal fragments (V1 and V2) of the YFP Venus variant. 32 We tagged a known binding partner of ILK, b-parvin, with the V1 fragment to use as a positive control for interaction with V2-ILK. As a negative control, the b-parvin binding-deficient ILK E359K variant 33 was V2-tagged, and co-transfected with V1-b-parvin into TSU-Pr1 cells. As expected, V1-b-parvin and V2-ILK demonstrated strong cytoplasmic interaction, whereas a significantly decreased level of signal was detected in cells coexpressing V1-b-parvin and V2-ILK E359K (Figures 6b and c) . We validated the specificity of p38b binding in BiFC using its known binding partner PRAK.
34 V2-PRAK was co-transfected into TSU-Pr1 cells with V1-p38b or a PRAK non-binding mutant V1-p38b nqn (mutated in the docking motif), 5 as respective positive and negative controls. PRAK interaction directs subcellular localization of p38 MAPKs 5 and accordingly, we observed a strong interaction between PRAK and wild-type p38b, but not p38b nqn in TSU-Pr1 cells (Figures 6b and c) . Having confirmed the specificity of ILK and p38b interactions, we co-transfected TSU-Pr1 cells with V1-p38b, or V1-p38g, and V2-ILK to test for direct interaction of ILK and these p38 isoforms. Cytoplasmic Venus signal was readily detected in cells co-expressing ILK and p38b, but not in those co-expressing ILK and p38g (Figures 6b and c) , supporting specific, direct interaction of ILK with the b isoform of p38 MAPK . We sought to localize the region of ILK that mediates p38b interaction by performing BiFC assays using V2-tagged truncations and function-disrupting ILK point mutants. Truncated V2-ILK variants containing the ankyrin repeat and pleckstrin homologylike domains (amino acids 1-213 and 1-293) did not interact with V1-p38b, whereas an N-terminal truncated ILK variant containing the pleckstrin homology-like and catalytic domains interacted equally well to wild-type ILK (Figures 6d-f) . A point mutation that has been shown to inhibit ILK catalytic activity, ILK K220M did not interact with p38b. Conversely, ILK E359K , which is deficient for b-parvin binding, and ILK R211A , which acts as a dominant-negative ILK signaling mutant, each bound to p38b (Figures 6d-f) . These results indicate that the ILK catalytic domain mediates its interaction with p38b, and further suggest that interaction requires ILK kinase activity.
In light of their interaction in the BiFC assays, it was important to test for association of endogenous ILK and p38b, which was performed using the in situ proximity ligation assay (PLA). 35, 36 Positive controls tested for interactions between ILK and two of its focal adhesion binding partners, Pinch and a-parvin. Using specific antibodies against ILK, Pinch, a-parvin and p38 for immunofluorescence, we observed predominantly cytoplasmic associations of ILK-parvin, ILK-Pinch and ILK-p38b in the TSU-Pr1 cells (Figures 7a-c) . As a negative control, we used concentration and isotype-matched mouse and rabbit control IgG that generated no signal. As our data show that ILK and p38b promote serum-induced migration of TSU-Pr1 cells, we next asked whether formation of endogenous ILK-p38 complexes is regulated by serum. ILK-p38 complexes were readily detected under both conditions of serum deprivation and stimulation, and treatment with 10% FBS stimulated a significant increase in cytoplasmic complex formation (Figures 7d and e) .
Our BiFC results showing lack of binding between p38b and the K220M catalytic mutant of ILK (Figure 6f ) 37 suggested that inhibiting ILK kinase activity would interfere with serum-induced assembly of ILK-p38b cytoplasmic complexes. In order to test this possibility, we performed PLAs on FBS-stimulated TSU-Pr1 cells that had been pretreated with the selective ILK kinase inhibitor QLT-0267 (see reference 37 ). In cells pretreated with 5 mM QLT-0267, FBS-induced chemotaxis was inhibited by about 50% (Figure 8a and b), therefore, we used this concentration to test for effects on complex assembly. FBS-stimulated assembly of cytoplasmic ILKp38b complexes was blocked by 5 mM QLT-0267 (Figures 8c and d) , suggesting that ILK kinase activity regulates its association with p38b in response to promigratory serum factors.
DISCUSSION
Our analysis of paired normal and bladder tumor tissues revealed a striking positive correlation between ILK and p38b protein levels, suggesting an important ILK-p38 MAPK signaling axis in the uroepithelium with potential implications for bladder cancer progression. We confirmed that the TSU-Pr1 bladder cancer cell model exhibits no expression level of MKK6, the major p38 regulators. 2 The most frequently studied p38 MAPK is the a isoform, however, p38b is also widely expressed, albeit typically at lower levels than p38a. It is clear that the multiple p38 MAPKs do not simply provide redundant signaling functions, with diverse isoform-specific roles in cancer having recently been discovered. 38 Thus, p38a inhibits hepatocyte proliferation and development of liver cancer in mice, 39 as well as suppressing Ras-induced transformation of mouse embryo fibroblasts in vitro 40 and lung tumorigenesis in vivo. 41 However, studies demonstrating p38a-and p38d-mediated invasiveness of head and neck squamous carcinoma cells, 42 and suppression of skin tumorigenesis in p38d-null mice, 43 highlight contextual After 24 h starvation, siRNA transfectants were treated with 10% FBS for the indicated times, then lysed for analysis by western blotting using phospho-specific and total protein antibodies to Hsp27, Akt, GSK3b, ERK1/2 and ILK. (b) For phosphorylated proteins, the ratio of phosphorylated:total species was determined by densitometry and normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels. Statistical difference between NTC and ILK siRNA groups was determined using two-way analysis of variance. **Po0.001, n ¼ 3, error bars ¼ s.e.m.
influences of distinct upstream regulators and substrate preferences in determining the oncogenic or tumor suppressive outcomes of p38 MAPK signaling. Our data uncover a novel role of ILK in selectively complexing with and stabilizing the p38b isoform, thereby promoting TSU-Pr1 cell migration and suggesting a role for the ILK-p38b axis in bladder cancer progression.
We have obtained evidence for the close physical interaction of ILK and p38b, using three independent methodologies to analyze protein interactions. In particular, BiFC and PLA techniques detect interactions between protein partners within tens of nanometers of each other, and also allow subcellular localization of complexes. We also detected ILK-p38b complexes using co-immunoprecipitation, indicating formation of stable complexes between these binding partners. Importantly, PLA confirmed interaction of endogenous ILK-p38b complexes. Assembly of these complexes is stimulated by serum treatment of cells, and assembly is apparently dependent on ILK kinase activity, as a catalytic mutant of ILK does not associate with p38b (Figures 6d-f ) and the selective ILK QLT-0267 inhibitor blocks serum induction of complexes (Figures 8c and d) . Based on the sizes of antibodies and oligonucleotide label in PLAs, we estimate ILK and p38b associate within 30-40 nm in these complexes, a distance also supported by our BiFC results.
The interaction of ILK and p38b occurs in the cytoplasm, removed from membrane-associated focal adhesions and canonical ILK-mediated integrin signaling. Taken together, our results MAPK , Akt and GSK3b were assessed in TSU-Pr1 and 5637 bladder cancer cells transfected with NTC-or ILK-specific siRNA. (b) mRNA levels of the four p38 isoforms were determined using real-time quantitative PCR, performed on RNA isolated 24 h after transfection of TSU-Pr1 cells with NTC or ILK siRNA. Specific primers were as described in Supplementary Table S1 . n ¼ 3, error bars ¼ s.e.m. (c) TSU-Pr1 cells were transfected with NTC or ILK siRNA for 48 h, then transfected with FLAG-p38b or p38g in order to determine the effect of ILK depletion on levels of the ectopically expressed p38 proteins. Phospho-p38, total FLAG-p38g and FLAG-p38b were detected after 72 h by western blots of whole-cell lysates. (d) Cells were transfected with either NTC or ILK siRNA, and after 72 h, cells were treated with MG132 at the indicated concentrations, for 6 h before lysis and western blotting. Densitometry was used to calculate the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-normalized percentage of p38b, for each transfectant at each MG132 concentration, relative to the NTC controls. V1-p38β degradation, whereas p38b is not degraded and mediates cytoprotective effects of HO-1. HO-1-induced degradation of p38a is partially rescued by MG132, 45 similar to our results with p38b. Treatment of TSU-Pr1 cells with ILK inhibitor QLT-0267 disrupts ILK-p38b complex assembly, and ILK inhibition in these cells inhibits p38 Thr180/Tyr182 phosphorylation. We do not know if this phosphorylation is required for p38b stability, however, as ILK is a serine/threonine protein kinase, 13, 37 it is unlikely that Tyr182 is directly phosphorylated by ILK, and it will be important to resolve these questions in order to understand regulation of p38b stability by ILK.
NTC
Although insignificant, the weak rescue of chemotactic migration by p38b transfection into ILK-depleted TSU-Pr1 cells may result from interaction with residual cellular ILK protein (Supplementary Figure S3) , and suggests that ILK and p38b act together in regulating actin reorganization and migration of bladder cancer cells. This likely occurs via a mechanism distinct from the previously reported ILK regulation of Rac1 activation via b-parvin and a-PIX, 21, 28, 46, 47 and serum-induced activation of the chaperone protein Hsp27 by ILK-p38b complexes may occur downstream of Rac1 (Supplementary Figure S7) . Hsp27 is phosphorylated by the PRAK, a direct target of p38 a and b isoforms, 34, 48 and activated Hsp27 regulates actin reorganization in endothelial cells, 30 as well as migration of squamous head and neck carcinoma cells. 31 Consistent with a role in tumor migration and invasiveness, Hsp27 overexpression has been linked to metastatic spread of prostate cancer, 49 hepatocellular carcinoma 50 and squamous cell cancer of the tongue. 51 Our work therefore identifies Hsp27 as a novel target for regulation by ILK-p38b protein complexes, with implications for actin remodeling underlying bladder cancer progression and metastasis. Cell culture and reagents TSU-Pr1 cells were obtained from Dr Dan Djakiew (Georgetown University, Washington, DC, USA).
MATERIALS AND METHODS
Tumor samples
52 B1 and B2 cell lines derived from TSU-Pr1were generated and cultured as previously described. 26 All other cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in the recommended media following ATCC instructions. The following antibodies were used for western blot analysis: mouse monoclonal anti-human ILK antibody (65. were all from Cell Signaling Technology (Danvers, MA, USA). Secondary antibodies were used as previously described. 53 Rac1 inhibitor NSC23776 was obtained from Santa Cruz Biotechnology.
Cell viability assay
Cell viability was measured over a period of 5 days using the Cell Titer-Glo Luminescent Cell viability assay (Promega, Fitchburg, WI, USA). Following the manufacturer's instructions, 3000 cells were seeded onto a 96-well plate in triplicate in growth medium. Each day, the Cell Titer-Glo reagent was added to the cells and luminescence read on a FLUOstar Optima from BMG LABTECH (Mornington, VIC, Australia).
Monolayer wound healing and microchemotaxic migration assay Cells were seeded in 24-well plates and treated with siRNA for 72 h and allowed to establish confluent monolayers. Monolayers were wounded using a sterile yellow pipette tip. The subsequent migration of cells into the wound was monitored as described previously. 53 For chemotactic migration assays, the wells of a microchemotaxis chamber (AP48, Neuro Probe, Gaithersburg, MD, USA), covered by an 8-mm pore size polycarbonate membrane, were seeded with 1 Â 10 5 cells. Cells were serum-starved for 24 h before starting the assay. Medium containing 10% FBS was used as attractant in the bottom wells, and cells were allowed to migrate for 16 h after initiation for siRNA experiments, and for 6 h in QLT-0267 and Rac1 inhibitor experiments. Nikon Eclipse 50i microscope (Nikon Instruments, Melville, NY, USA) was used to capture images. The number of cells that had passed through the membrane was counted using Image J software (NIH, Rockville, MD, USA).
Small GTPase activity assay TSU-Pr1 cells were cultured to 50% confluent as a monolayer in a 10-cm Petri dish. After incubation in 0.1% FBS-DMEM for 24 h followed by serumfree medium overnight, cells were treated with epidermal growth factor (10 ng/ml as final concentration) at time points (or 10% FBS for 2 min). The levels of GTP-bound RhoA, Rac1 and Cdc42 were measured using the appropriate activation assay kit (Cytoskeleton, Denver, CO, USA) according to the manufacturer's instructions. Whole-cell lysates were loaded with GTPgS or GDP, as respective positive and negative controls.
In situ PLA
In situ PLA and quantification were performed as previously described. 53 Briefly, cells were plated into 24-well plates on coverslips at a density of 25 000 cells/well and grown in medium overnight, then fixed in 10% buffered formalin (ORION Laboratories, Balcatta, WA, Australia). After blocking for 30 min at 37 1C with blocking solution, the primary antibodies were then added to each sample at previously optimized dilutions: ILK 65.1 at 1:200; total p38 at 1:100 (#9212, Cell Signaling Technology); PINCH at 1:100 (ab50305, Abcam, Cambridge, UK); a-parvin at 1:100 (#4026, Cell Signaling Technology) followed by 1 h incubation at room temperature. PLA probe (mouse and rabbit) solutions (1:5) were added to each sample followed by 1 h incubation at 37 1C. After washes, Ligation-Ligase solution and Amplification-Polymerase solution were added, respectively, as the manufacturer's instructions. The slides were then washed, dried and mounted. All PLA experiments were imaged on a Nikon C1 confocal (TexasRed settings) at Â 60 magnification with 10 fields of view between 5 and 20 cells per image. All images were analyzed using OLINK image tool software (OLINK Bioscience, Uppsala, Sweden). Deltavision algorithm. The image analyses were processed in the Bitplane Imaris software as previously described. 54 Split Venus experiments were imaged on a Nikon C1 confocal (GFP settings) with 10 fields of view, between 2 and 10 cells per image. All images were analyzed by Image J software.
Transfection and RNA interference Cells (50-60% confluent) were transfected with non-or gene-targeted siRNAs at 20 nM from Thermo Scientific Dharmacon (Lafayette, CO, USA): ILK (cat# L-004499), p38b (cat# L-003972), p38g (cat# L-003590) and scrambled control (cat# D-001810) using Lipofectamine 2000 (Invitrogen). Cells were incubated for 72 h before migration assays, small GTPase activity assay and protein extraction. For expression studies, cells were transfected in Petri dish for co-immunoprecipitation with FLAG-tagged vectors (2 mg) or on coverslips in 24-well plates with FLAG-tagged (400 ng) or Venustagged (30 ng of each V1 and V2) plasmids using Fugene HD (Roche, Hawthorn, VIC, Australia) according to the manufacturer's instructions.
Construction of protein expression vectors and mutagenesis FLAG-tagged p38b, p38g and GFP-tagged PRAK were kindly provided by Professor Jiahuai Han (Xiamen University, China). Split Venus plasmids (referred to as V1 and V2) were kindly provided by Drs Stephen Michnick and Jean-Franc¸ois Paradis (University of Montreal, Canada). The coding region of each gene (human sequence) was subcloned into one or both vectors in-frame with the fluorophore. Various mutations were created by using the Quick Change kit (Stratagene, La Jolla, CA, USA) and using corresponding pairs of mutagenic oligonucleotides. Each mutation was confirmed by Sanger DNA sequencing.
Real-time quantitative PCR
Total RNA was isolated using Trizol (Invitrogen). One microgram of total RNA was used in each complementary DNA synthesis reaction and 10 ng of complementary DNA was used in each PCR reaction. Primers and probe sequences are described in Supplementary Table S1 . All protocols were used as we have described previously. 53 
Western blotting and immunoprecipitation
In stimulation experiments, TSU-Pr1 cells were incubated in 0.1% serum medium overnight, then starved for 24 h before ligand stimulation with either 10% FBS or serum-free media for the indicated time points. RIPA buffer was used to extract protein from the cell monolayer. All protocols were performed as previously described. 53 For immunoprecipitation, total cell lysates were incubated with ILK, anti-FLAG or isotype IgG, and protein pulled down using agarose beads. Protein samples were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and immunoblotted with the indicated antibodies. Signals were visualized using an Odyssey Infrared Imaging System (Li-Cor, Lincoln, NB, USA).
Statistical analyses
Student's t-test was used to calculate statistical significance, with Po0.05 defined as a statistically significant difference. Correlation analysis was carried out using Pearson's method. The levels of phosphorylation of kinases at time course and wound healing migration were conducted using two-way analysis of variance. All calculations were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). All experiments had at least three technical and three biological replicates.
